Fig. 1.

Snapshot analysis of the proportion of participants with plasma HIV-1 RNA <50 copies/ml (a) by visit and (b) in the GEMINI-1, GEMINI-2, and pooled ITT-E populations at week 144, with adjusted treatment differences (95% CI).

CI, confidence interval; DTG, dolutegravir; FTC, emtricitabine; ITT-E, intention-to-treat-exposed; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate. ^aBased on Cochran–Mantel–Haenszel stratified analysis adjusting for baseline plasma HIV-1 RNA (≤100 000 vs. >100 000 copies/ml), baseline CD4⁺ cell count (≤200 vs. >200 cells/μl), and study (GEMINI-1 vs. GEMINI-2).